Browse News
Filter News
Found 131 articles
-
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements
3/6/2024
Antion Biosciences announces achievement of two significant milestones that underscore the uniquely powerful, multiplex engineering capability of its technology platform.
-
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
2/29/2024
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, highlighted recent updates on the progress made within key areas of its proprietary End-to-End Platform, at the 7th CAR-TCR Summit Europe taking place in London from February 27-29, 2024.
-
BioIVT Announces Expansive Fresh Leukopak Capability in Europe
2/22/2024
BioIVT announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks.
-
Medigene to Present at Upcoming Conferences
2/19/2024
Medigene AG will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore.
-
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe
2/15/2024
TC BioPharm PLC announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured "Expert Speakers" at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.
-
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
1/16/2024
Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
-
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones
1/4/2024
Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, highlighted recent progress across the company's cell and gene therapy portfolio and provided updates on anticipated upcoming milestones.
-
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
12/21/2023
Marker Therapeutics, Inc. announced that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit.
-
Umoja Biopharma Presents Preclinical Data at the 65th American Society of Hematology Annual Meeting Demonstrating In Vivo CAR T Cell Generation with Potent and Highly Durable Activity
12/11/2023
Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments for cancers and other indications of high unmet need, today announced proof-of-concept preclinical data evaluating the company’s VivoVec™ in vivo gene delivery technology to generate chimeric antigen receptor (CAR) T cells in vivo in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023, in San Diego, California.
-
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
11/9/2023
Celyad Oncology, a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, reports its financial results for the third quarter of 2023 and provides an update on recent business developments.
-
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
11/9/2023
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates.
-
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
11/9/2023
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023.
-
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
9/4/2023
Celyad Oncology, announces its financial results and recent business developments for the first half year, ended June 30, 2023.
-
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit
9/1/2023
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will present findings today at the 8th Annual CAR-TCR Summit from its Phase 1 clinical trial of the Company's lead product candidate, CT-0508.
-
Umoja Biopharma’s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-Human Primate Study at the 8th CAR-TCR Summit
9/1/2023
Umoja Biopharma, Inc. today announced new data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the Company’s VivoVec™ platform technology at the 8th CAR-TCR Summit taking place in Boston, MA, August 29 - September 1, 2023.
-
Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes
8/30/2023
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.
-
Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events
8/28/2023
Abata Therapeutics, a company focused on translating the biology of regulatory T cells into transformational medicines for patients living with severe autoimmune and inflammatory diseases, announced that company leadership will present and participate in the following investor and industry events.
-
XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston
8/28/2023
XNK Therapeutics AB announced that Linda Brick, Head of QA, will be speaking at the 8th CAR-TCR Summit in Boston.
-
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023
8/24/2023
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023.
-
Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit
8/23/2023
Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary best-in-class data from an ongoing non-human primate study for the first time at the 8th CAR-TCR Summit being held August 29-September 1 in Boston, MA.